Endocrinologist Reflects on Rosiglitazone
Posted on 22. Jul, 2010 by Dr. Ellis in News and Updates
WASHINGTON (MedPage Today) — As the FDA processes the vote and discussion from last week’s advisory committee meeting on rosiglitazone (Avandia), an endocrinologist who has twice voted to keep the diabetes drug on the market dissected what the recent vote means in a perspective published in the New England Journal of Medicine.
Read Full Article…
Possibly Related Blogs
FDA Staffers Blast Rosiglitazone at Advisory Panel Meeting
Posted on 13. Jul, 2010 by Dr. Ellis in News and Updates
GAITHERSBURG, Md. (MedPage Today) — The two major FDA critics of rosiglitazone (Avandia) again denounced the diabetes drug during the first day of an advisory committee meeting that will end with a vote on whether the agency should pull it from the market.
Read Full Article…
Possibly Related Blogs
Take Rosiglitazone Off the Market, Says FDA Staff
Posted on 09. Jul, 2010 by Dr. Ellis in News and Updates
WASHINGTON (MedPage Today) — Rosiglitazone (Avandia) should be pulled from the market because of the “serious” cardiovascular risk the diabetes drug poses, which exceeds that of competitor pioglitazone (Actos), FDA staff reviewers again recommended.
Read Full Article…
Possibly Related Blogs
CODHy: Diabetes Docs Skeptical of FDA Drug Safety Policy
Posted on 14. May, 2010 by Dr. Ellis in News and Updates
PRAGUE (MedPage Today) — At least some in the diabetes community remain unconvinced that the FDA’s demand for extensive cardiovascular safety data on new drugs will ultimately help patients, researchers indicated here.
Read Full Article…
